Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study  by Di Biase, Luigi et al.
Does periprocedural anticoagulation management of
atrial ﬁbrillation affect the prevalence of silent
thromboembolic lesion detected by diffusion cerebral
magnetic resonance imaging in patients undergoing
radiofrequency atrial ﬁbrillation ablation with open
irrigated catheters? Results from a prospective
multicenter study
Luigi Di Biase, MD, PhD, FHRS,*†‡§ Fiorenzo Gaita, MD,ǁ Elisabetta Toso, MD,ǁ
Pasquale Santangeli, MD,*§ Prasant Mohanty, MBBS, MPH,* Neal Rutledge, MD,# Xue Yan,*
Sanghamitra Mohanty, MD,* Chintan Trivedi, MD, MPH,* Rong Bai, MD, FHRS,*
Justin Price, BS,* Rodney Horton, MD,* G. Joseph Gallinghouse, MD,* Salwa Beheiry, RN,*
Jason Zagrodzky, MD,* Robert Canby, MD,* Jean François Leclercq, MD,ǁǁ Franck Halimi, MD,**
Marco Scaglione, MD,†† Federico Cesarani, MD,‡‡ Riccardo Faletti, MD,§§
Javier Sanchez, MD,* J. David Burkhardt, MD, FHRS,* Andrea Natale, MD, FHRS*‡ǁǁ##***
From the *Texas Cardiac Arrhythmia Institute at St. David’s Medical Center, Austin, Texas, †Albert Einstein
College of Medicine at Monteﬁore Hospital, New York, New York, ‡Department of Biomedical Engineering,
University of Texas, Austin, Texas, §Department of Cardiology, University of Foggia, Foggia, Italy,
ǁDepartment of Medical Sciences, University of Turin, Turin, Italy, #Austin Radiological Association, Austin,
Texas, **Department of Rythmology, CMC Parly II Le Chesnay, Le Chesnay, France, ††Division of Cardiology,
Cardinal Guglielmo Massaia Hospital, Asti, Italy, ‡‡Division of Radiology, Cardinal Guglielmo Massaia
Hospital, Asti, Italy, §§Radiology Institute, Department of Surgical Sciences, University of Turin, Turin, Italy,
ǁǁCalifornia Paciﬁc Medical Center, San Francisco, California, ##Division of Cardiology, Stanford University,
Palo Alto, California and ***Heart and Vascular Center, Case Western Reserve University, Cleveland, Ohio.BACKGROUND Silent cerebral ischemia (SCI) has been reported in
14% of cases after catheter ablation of atrial ﬁbrillation (AF) with
radiofrequency (RF) energy and discontinuation of warfarin before
AF ablation procedures.
OBJECTIVE The purpose of this study was to determine whether
periprocedural anticoagulation management affects the incidence
of SCI after RF ablation using an open irrigated catheter.
METHODS Consecutive patients undergoing RF ablation for AF
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a group of patients who had protocol deviation in terms of main-
taining the therapeutic preprocedural international normalized ratio
(patients with subtherapeutic INR) and/or failure to receive pre-
transseptal heparin bolus infusion and/or Z2 consecutive ACT
measurements o300 seconds (noncompliant population, group II,
n ¼ 134) and with a group of patients undergoing RF ablation
with warfarin discontinuation bridged with low molecular weight
heparin (group III, n ¼ 148). All patients underwent preablation
and postablation (within 48 hours) diffusion magnetic resonance
imaging.
RESULTS SCI was detected in 2% of patients (3/146) in group I,
7% (10/134) in group II, and 14% (21/148) in group III
(P o.001). “Therapeutic INR” was strongly associated with a
lower prevalence of postprocedural silent cerebral ischemia
(SCI). Multivariable analysis demonstrated nonparoxysmal AF
(odds ratio 3.8, 95% conﬁdence interval 1.5–9.7, P ¼ .005) and
noncompliance to protocol (odds ratio 2.8, 95% conﬁdence
interval 1.5–5.1, Po.001] to be signiﬁcant predictors of ischemic
events.http://dx.doi.org/10.1016/j.hrthm.2014.03.003
Heart Rhythm, Vol 11, No 5, May 2014792CONCLUSION Strict adherence to an anticoagulation protocol
signiﬁcantly reduces the prevalence of SCI after catheter ablation
of AF with RF energy.
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ABBREVIATIONS ACT ¼ activated clotting time; AF ¼ atrial
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Atrial ﬁbrillation (AF) is the most frequent supraventricular
arrhythmia and has been associated with an increased risk of
death, stroke, and hospitalization.1–5 Radiofrequency (RF)
catheter ablation (CA) has proven to be an effective treat-
ment strategy for AF.6 However, the ablation procedure itself
is associated with a potential risk for iatrogenic periproce-
dural stroke.6–10 Advancements in ablation catheters and
strategies and improvements in periprocedural anticoagula-
tion management have reduced such complications and have
also improved the procedural success.6–10 Nevertheless,
because of the invasive and complex nature of CA, the
incidence of thromboembolic events in ablation cases is still
1% to 5% (depending on ablation catheter used, antico-
agulation strategy in the periprocedural period, and type of
patients included in the study).10,11
In addition to stroke/transient ischemic attack (TIA),
silent cerebral ischemia (SCI) represents an emerging
complication of CA.12 Therefore, stroke and TIA may
represent only the tip of the iceberg.7,8,10,11 Gaita et al12
performed diffusion magnetic resonance imaging (dMRI)
before and after RFCA. They demonstrated that SCI was
more prevalent than clinical periprocedural thromboembolic
events, reporting a SCI prevalence of up to 14%. Further-
more, a signiﬁcant correlation between SCI and reduced
cognitive performance has recently been reported.13
Although the effects of symptomatic stroke are notably
dramatic for patients, SCI also is worrisome because it
signiﬁcantly increases the likelihood of further cerebral
damage in a patient population that already is at higher risk
for cerebral embolism and dementia.5,14 This implication is
notable for physicians because patients undergoing RFCA
procedures will undergo repeat ablations in 30% to 50% of
cases, raising the possibility for cumulative damage.15 The
energy source and ablation technology used seem to inﬂu-
ence the prevalence of SCI, which is as high as 38% in some
cases.12,16–22
Periprocedural thromboembolic complications potentially
could be prevented by making adjustments to the manage-
ment of anticoagulation before and after CA.10,11 At present,
data on treatment of SCI using any energy source or
technology have been reported for periprocedural antico-
agulation management that includes warfarin discontinua-
tion before the procedure and a “bridge” with low molecular
weight heparin 3 to 5 days before the procedure and then
restart with warfarin after the procedure.12,16–22 The role ofperiprocedural anticoagulation management in SCI preven-
tion has not been widely investigated. Because stroke and
TIA rates during AF ablation have been dramatically reduced
with the performance of CA for AF without warfarin
discontinuation,10,11 we sought to assess whether strict
periprocedural anticoagulation management could affect
the prevalence of SCI after RFCA using open irrigated
catheters.Methods
Consecutive patients undergoing RFCA for symptomatic
and drug-refractory AF and under “therapeutic” warfarin
were included in this prospective multicenter study. All
patients included in the study were matched with a control
population of consecutive patients undergoing RFCA in the
same time period at each enrolling institution but with
warfarin discontinuation before CA that was bridged with
low molecular weight heparin.10 Anticoagulation treatment
before ablation was decided by the treating electrophysiol-
ogist based on his or her preference. The deﬁnitions of AF
followed those of the American Heart Association and the
Heart Rhythm Society.23
All patients underwent preablation and postablation
(within 48 hours) dMRI. Exclusion criteria were age o18
years or 480 years, valvular heart disease with surgical
indication, acute coronary syndrome o3 months, or other
contraindications to dMRI. All patients provided written
informed consent. The study was approved by the Institu-
tional Review Board of each institution.Periprocedural anticoagulation management
Patients undergoing ablation without warfarin
discontinuation (on warfarin)
Warfarin was initiated 4-6 weeks before the ablation
procedure, and a “therapeutic international normalized ratio
(INR) range” for 4 weeks before the procedure was
requested. Warfarin was not stopped the night before the
procedure and was taken the night of the procedure. Trans-
esophageal echocardiography was performed only in
patients without sinus rhythm the day of the procedure and
if they presented to the electrophysiology laboratory with a
subtherapeutic INR on the day of procedure. Patients with a
subtherapeutic INR on the day of the procedure were
included in the study. If INR was43.5, patients were given
1 to 2 units of fresh frozen plasma before the procedure.
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nous bolus of heparin 10,000 international units (IU) was
administered in males and 8000 IU in females irrespective of
body weight. During the procedure, activated clotting time
(ACT) was checked every 20 minutes, and additional heparin
boluses were administered as needed to maintain ACT4300
seconds. The transseptal sheaths were continuously infused
with heparinized saline (2000 IU per 250-mL bag) during the
entire procedure. RF energy was delivered with a 3.5-mm
open irrigated ablation catheter (Biosense Webster, Baldwin
Park, CA) with a maximum temperature of 421C, power up
to 45 W, and ﬂow rate of 30 cc/min with heparinized ﬂuids.
After ablation was completed in the left atrium (LA),
heparin was partially reversed with protamine guided by the
ACT values. Sheaths were removed when ACT was o200
seconds. In case of perforation with cardiac tamponade,
heparin was stopped and reversed with protamine. Fresh
frozen plasma was used to reverse the warfarin effect.Patients undergoing ablation with warfarin
discontinuation (off warfarin)
Warfarin was initiated 4-6 weeks before the ablation
procedure, and a “therapeutic INR range” for 4 weeks before
the procedure was requested. Warfarin was discontinued 3
days before the ablation procedure, and enoxaparin 0.5 mg/
kg was administered until 12 hours before the procedure
twice per day. An intravenous bolus of heparin of 15000 IU
was given before the transseptal puncture. A continuous
infusion of heparin 1000 U/h was started. The infusion was
adjusted to maintain ACT 4300 seconds.
All patients underwent transesophageal echocardiography
before ablation to rule out the presence of LA thrombus. At
the end of the procedure, protamine was given to partially
reverse the heparin effect. Warfarin was restarted the evening
of the procedure. In addition, enoxaparin 0.5 mg/kg bid was
routinely started about 3 hours after the sheaths were
removed and was stopped when the INR reached a “ther-
apeutic range.” During the procedure, ACT was checked
every 20 minutes, and additional heparin boluses were
administered as needed to maintain ACT 4300 seconds.
The transseptal sheaths were continuously infused with
heparinized saline (2000 IU per 250-mL bag) during the
entire procedure. RF energy was delivered with a 3.5-mm
open irrigated ablation catheter (Biosense Webster) with a
maximum temperature of 421C, power up to 45 W, and ﬂow
rate of 30 cc/min with heparinized ﬂuids. Sheaths were
removed when ACT was o200 seconds. In case of
perforation with cardiac tamponade, heparin was stopped
and reversed with protamine.Electrophysiologic study and ablation procedure
Our approach has been described in detail elsewhere.12,23–25
Brieﬂy, antiarrhythmic drugs were discontinued 4 to 5 half-
lives before ablation. A double transseptal access was
performed in all patients. A circular mapping catheter
(Lasso, Biosense Webster) was used to guide the ablationtogether with intracardiac echocardiography, and a 3.5-mm
open irrigation tip catheter (ThermoCool, Biosense Webster)
were used for ablation. In all patients with paroxysmal atrial
ﬁbrillation (PAF), pulmonary vein (PV) antrum isolation was
performed. Isolation of the PV antrum could be extended to
the posterior wall. The superior vena cava also was isolated if
PV-like potentials were recorded in that region. In patients
with nonparoxysmal atrial ﬁbrillation (NPAF), electrical
isolation of the PV antrum was extended to the entire
posterior wall down to the coronary sinus and to the left
part of the septum. Complex fractionated atrial electrograms
were ablated as well. The LA appendage and coronary sinus
could be isolated when deemed to be necessary. After
ablation, isoproterenol challenge (up to 30 μg/min) was
performed to reveal non-PV triggers or to exclude the
presence of PV reconnection. Non-PV triggers were deﬁned
as any sustained and nonsustained ﬁring sites outside
the PVs.
dMRI
All patients underwent preablation and postablation (within
48 hours) dMRI. Radiologists who read the MRI scans were
blinded to anticoagulation status. The MRI protocol used has
been described in detail elsewhere.12,13 In brief, images at
each different site were obtained using 1.5-T clinical MRI
(GE Healthcare, Waukesha, WI, and Siemens Vision Plus,
Erlangen, Germany) scanners according to standard proto-
cols. These protocols contained (1) T1 sagittal, (2) DWI
axial, (3) ﬂair axial, (4) T2 axial, (5) T1 axial, (6) T2*
coronal, and (7) GRE-EPI coronal images as needed to
delineate acute lesions within 48 hours compared to prea-
blation scans. Neuroanatomic localization and characteristics
were assessed and recorded, separating acute infarct and
hemorrhages from unaffected subjects.
Statistical analysis
Continuous data are reported as mean  SD or as count and
percent if categorical. The Student t test, one-way analysis of
variance, χ2 test, and Fisher exact test were used to compare
differences across groups. Univariate and multivariate logis-
tic regression was used for identifying independent predic-
tors of silent thromboembolic stroke. Potential confounders
entered into the multivariable model were identiﬁed based on
known clinical relevance or signiﬁcant association observed
in univariate analysis. The controlling variables used in the
model were age, gender, LA diameter, CHADS2 score, and
AF type. Tests were run to determine the presence of multi-
colinearity of the covariates. Odds ratio (OR) and 95% con-
ﬁdence interval (CI) of SCI were computed. All tests were
2-sided, and P o.05 was considered signiﬁcant. Analyses
were performed using SAS 9.2 (SAS Institute, Cary, NC).
Results
A total of 280 consecutive patients undergoing CA for AF on
warfarin and a matched control population of 148 patients
(group III patients) undergoing RF ablation off warfarin were
Table 1 Baseline characteristics
Group I
(n ¼ 146)
Group II
(noncompliant, n ¼ 134)
Group III
(n ¼ 148) P value
Male 114 (78) 105 (78) 115 (78) 1
Age (years) 59  9 58  9 58  10 .58
Atrial ﬁbrillation type
Paroxysmal 38 (26) 40 (30) 55 (37) .11
Persistent 47 (32) 42 (31) 50 (34) 1
Long-standing persistent 61 (42) 54 (40) 46 (31) .14
Cardioversion 38 (26) 24 (18) 40 (27) .15
ACT during procedure (seconds) 362  35 356  42 348  64 .08
CHADS2 score Z2 28 (19) 24 (18) 20 (14) .39
Left ventricular ejection fraction (%) 58  8 58  11 60  10 .13
Left atrial diameter (cm) 4.6  0.7 4.4  0.7 4.3  0.8 o.01
Coronary artery disease 31 (21) 21 (16) 24 (16) .41
Hypertension 69 (47) 54 (40) 58 (39) .32
Dyslipidemia 35 (24) 29 (22) 28 (19) .58
Body mass index 29  6 29  6 29  5 .40
Congestive heart failure 7 (5) 8 (6) 4 (3) .39
Diabetes 32 (22) 28 (21) 40 (27) .42
Values are given as no. (%) or mean  SD. ACT = Activated clotting time.
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Figure 1 Incidence of silent cerebral ischemia in the 3 groups sorted by
rhythm on the day of the procedure. AF ¼ atrial ﬁbrillation; AT ¼ atrial
tachycardia; SR ¼ sinus rhythm.
Heart Rhythm, Vol 11, No 5, May 2014794included in the study. Of the 280 patients on warfarin, 146
maintained a therapeutic INR, received heparin bolus before
transseptal catheterization, and all had ACT 4300 seconds
(group I patients, compliant to protocol group), whereas 134
had an anticoagulation protocol deviation: failed to maintain
a therapeutic preprocedural INR, had a subtherapeutic INR,
and/or failed to receive pretransseptal heparin bolus infusion
or had at least 2 consecutive ACTo300 seconds (group II,
noncompliant population). Baseline characteristics of the 3
groups did not show any statistical difference and are summ-
arized in Table 1.
Procedural results
Sixty-two percent of patients (n ¼ 91) in group I , 64% in
group II (n ¼ 86), and 54% (n ¼ 80) in group III entered the
electrophysiology laboratory in AF/atrial tachycardia (P ¼
.18). Persistence of AF/atrial tachycardia at the end of the
procedure was observed in 38 patients (26%) in group I, 24
patients (18%) in group II, and 40 patients (27%) in group III
(P ¼ .15). Sinus rhythm was achieved in these patients by
electrical cardioversion.
Mean procedural time was 165  62 minutes, 157  56
minutes, and 152  48 minutes (P ¼ .16) and RF ablation
times were 78 32 minutes, 75 30 minutes, and 69 35
minutes (P ¼ .12) for groups I, II, and III, respectively.
Clinical TIA/stroke
A periprocedural symptomatic TIA occurred in a group II
patient with long-standing persistent AF and subtherapeutic
INR of 1.6 on the day of the procedure. Two periprocedural
strokes occurred in group III patients and both had long-
standing persistent AF and CHADS2 score of 3 and 4,
respectively. No TIA/strokes occurred in group I patients.
Preablation SCI
SCI preablation did not differ among groups: 44% positive SCI
in group I, 42% in group II, and 43% in group III (P ¼ .94).Postablation SCI
SCI at postprocedure dMRI was detected in 2% (3/146) in
group I, 7% (10/134) in group II, and 14% (21/148) in
group III (P o.001). Figure 1 shows the results sorted by
rhythm on the day of the procedure. The 3 patients in group
I had small single lesions with diameters of 2.5 mm, 3 mm,
and 4 mm (Figure 2). The group II patients had lesions that
also were single and ranged in diameter from a minimum
of 4 mm up to 8 mm (Figure 3). The incidence of SCI in
group III patients was signiﬁcantly higher than in groups I
and II (Po.001 and Po.04, respectively), with 2 lesions
that reached approximately 30 mm in diameter and
5 patients (4%) who reported multiple (2-3) lesions
(Figure 4).Predictors of SCI
Risk of SCI according to baseline risk factors was assessed
using a univariate logistic model. AF type (OR 3.9, 95% CI
1.64–9.36, P ¼ .002) and subtherapeutic INR before the
Figure 2 Positive diffusion magnetic resonance imaging (red arrow)
showing a single lesion o5 mm in diameter in a group I patient with
nonparoxysmal atrial ﬁbrillation.
Figure 4 Bilateral parietal embolic lacunar infarct (red arrows) in a group
III patient. Both lesions appear to be45 mm in diameter.
795Di Biase et al Silent Cerebral Ischemia and AF Ablationprocedure (OR 3.1, 95% CI 1.45–10.2, P ¼ .006) showed
strong prognostic association with SCI. In addition, non-
compliance with the speciﬁed periprocedural anticoagulation
protocol with the targeted ACT level demonstrated higher
risk for SCI. ACT o300 seconds (observed on at least 2
consecutive measurements) during the procedure and no
administration of heparin bolus before transseptal catheter-
ization had univariate OR of 3.2 (P ¼ .005) and 1.6 (P ¼
.01), respectively. However, no association was seen
between LA time and SCI in the overall population
(OR 1.003, 95% CI 0.96–1.01, P ¼ .36). When examining
the population off warfarin, LA time demonstrated
signiﬁcant association (OR 1.05, 95% CI 1.004–1.07, P ¼
.028). Results from the univariate analysis are given in
Table 2.Figure 3 Positive diffusion magnetic resonance imaging (red arrow) in two grou
small embolic lacunar infarcts. No bleeds or cortical infarcts are seen.Multivariate analysis was performed using the logistic
regression model (model 1). The signiﬁcant confounders
identiﬁed in the univariate test were included in the model.
After adjusting for the confounders, subtherapeutic INR and
ACT o300 seconds during the procedure were strongly
associated with postprocedural SCI (OR 2.8, 95% CI 1.5–
5.1, P o.001, and OR 1.8, 95% CI 1.2–2.68, P ¼ .003,
respectively). Furthermore, multivariable analysis revealed
that NPAF independently predicted SCI (OR 3.8, 95% CI
1.5–9.7, P ¼ .005), and cardioversion did not show any
signiﬁcant association at either the univariate (OR 1.04, 95%
CI 0.89–1.03, P ¼ .371) or multivariate level (OR 2.1, 95%
CI 0.6–7.2, P ¼ .244). In group I patients, all 3 eventsp II patients who were noncompliant to protocol. Lesions appear to be single
Table 2 Univariate association of baseline risk factors with silent ischemic attack
Odds ratio 95% Conﬁdence interval P value
Age (years) 1.01 0.95–1.07 .753
Gender (female) 1.11 0.99–1.03 .271
Atrial ﬁbrillation type 3.923 1.64–9.36 .002
Cardioversion 1.04 0.89–1.03 .371
Hypertension 0.998 0.95–1.05 .939
Body mass index 1.07 0.96–1.18 .225
Diabetes 1.38 0.95–1.78 .12
CHADS2 score 1.32 0.87–2.63 .27
Left ventricular ejection fraction (%) 0.977 0.91–1.05 .535
Left atrial diameter (cm) 0.998 0.96–1.04 .939
Subtherapeutic international normalized ratio 3.088 1.45–10.02 .006
Activated clotting time o300 seconds 3.2 1.26–4.5 .005
Left atrial time (minutes) 1.003 0.96–1.01 .36
No heparin bolus before transseptal catheterization 1.63 1.16–2.3 .011
Heart Rhythm, Vol 11, No 5, May 2014796(100%) occurred in the non-PAF population, whereas in
group III patients (off warfarin), 62% of events were reported
in those with PAF and 38% in those with persistent AF.Discussion
Main ﬁndings
This is the ﬁrst large prospective study that sought to detect
SCI assessed by dMRI after RFCA of AF using an open
irrigated catheter while on uninterrupted warfarin with a
“therapeutic” INR. We showed that performing CA with
“therapeutic INR” and strict adherence to an anticoagula-
tion protocol that includes pretransseptal catheterization
intravenous heparin bolus and ACT 4300 seconds sig-
niﬁcantly reduces the prevalence of SCI compared to
patients off warfarin and those noncompliant with the
anticoagulation protocol. In addition, SCI occurred pre-
dominantly in patients with long-standing persistent AF in
whom extensive LA ablation was performed. Of note is
the ﬁnding that SCI did not correlate with electrical
cardioversion.
Another important ﬁnding is that all lesions that occurred
in the group on warfarin were single and had a diametero5
mm. Considering the potential cumulative damage of SCI
due to repeat procedures, especially in NPAF patients,15 the
drastic reduction of SCI obtained with therapeutic INR
appears to be of utmost importance even though no link
between SCI and neurocognitive function has yet been
proven.
Schwarz et al26 found no correlation between cognitive
decline and MRI-detected acute brain lesions after ablation.
Similarly, Herm et al27 observed no signiﬁcant alteration in
attention and executive functions, memory, and learning at
6-month follow-up in a prospective trial with long-term
follow-up MRI data. In contrast, Gaita et al13 recently
showed that patients with AF and positive asymptomatic
ﬁndings at MRI have a worse cognitive performance
compared to patients in sinus rhythm. Therefore, the results
of our study showing a signiﬁcant reduction of SCI could be
clinically relevant, although this study was not designed to
address this issue.Possible explanation of our ﬁndings compared with
previous studies can be summarized as follows. In all
previous studies, warfarin was discontinued before ablation,
thus modifying its protective effect. This is clearly shown by
the fact that subtherapeutic INR on the day of the procedure
increased SCI prevalence from 2% to 7 %. Full-dose heparin
bolus administration before transseptal catheterization is
another relevant issue. As shown in 2005 by Tse et al,28
heparin has an important role in preventing or blocking
platelet activation, which occurs immediately after sheaths
are inserted into the body. Warfarin has no role in preventing
or blocking platelet activation. We showed that in up to 9%
of patients either on or off warfarin, thrombus on the sheath
in the right atrium, visualized by intracardiac echocardiog-
raphy, was present before transseptal catheterization.29
Following the observations of Gaita et al12 on the prevalence
of SCI in patients who had undergone CA with RF energy,
SCI has been reported with use of different energy sources
and different technologies. SCI have been detected in 8% to
41% of all patients after CA.16,18,30,31 For all published data,
the common method of periprocedural anticoagulation was
discontinuation of warfarin and bridge with low molecular
weight heparin.12,16–22
This is the ﬁrst study assessing the prevalence of SCI in
patients who were kept on therapeutic warfarin and adhered
to a strict anticoagulation protocol. The study clearly showed
no occurrences of symptomatic stroke in patients who were
kept on warfarin. In their pilot study, Gaita et al12 concluded
that the incidence of SCI was heavily correlated with
cardioversion during the ablation procedure. In contrast,
the present study shows that a strict anticoagulation protocol
and not cardioversion signiﬁcantly reduces the occurrence of
SCI. Notably, many of our patients were NPAF and had
undergone extensive LA ablation.
Several other considerations should be taken into account
when comparing the 3 groups in this study. The baseline
characteristics of the patients and procedural parameters
were similar among groups (e.g., AF type, previous stroke,
arrhythmia duration, thrombotic predisposition, number of
RF lesions, LA procedural time), so no confounding factors
biased our results. During the procedures, several
797Di Biase et al Silent Cerebral Ischemia and AF Ablationmeasurements of ACT wereo300 seconds in groups II and
III but never in group I. This might have played an important
role that is attributable to the “therapeutic” warfarin effect.
Management of sheaths and foreign bodies was similar
among groups. Although a signiﬁcant reduction of SCI
was observed in group I, the role of air embolism determin-
ing SCI is still controversial.
Predictors for SCI
Recent studies have identiﬁed ACT,12,19 intraprocedural
electrical cardioversion,12,19 preablation transesophageal
echo contrast,16 and extensive LA ablation of complex
fractionated atrial electrograms and other structures as
independent predictors of SCI. Although data on all of these
variables are controversial, our study, which includes many
patients with NPAF, provides some insight into the issue of
SCI.12,16,18,31,32
Recent animal studies have indicated that MRI-detected
SCI are the results of cerebral ischemic lesions and lead to
glial scarring. These lesions may not be appropriately
detected using current MRI technology.33,34 The fact that
many of these lesions regress over time may be due to a
limitation in current diffusion MRI techniques and does not
necessarily reﬂect their disappearance. Haines et al33,34
showed in an animal study that SCI usually resolves on
MRI within 4 days after occurrence despite the presence of
permanent brain lesions at pathologic examination. Whether
smaller and larger SCI represent different mechanisms (air
embolism vs thrombotic embolism) requires further
evaluation.
Study limitations
The main limitation of our study is the absence of formal
randomization. Although we acknowledge this limitation, all
of the study data were collected in a prospective fashion, and
all procedures were performed in the same time period, thus
eliminating confounding factors such as operator experience
and technology advancements. Another limitation of the
study is that RF energy was the only ablation energy source
tested in this study. MRI were not interpreted using a core
laboratory. Finally, no neurocognitive tests were performed
before and after ablation.
Conclusion
This study shows that when RFCA of AF is performed under
“therapeutic” warfarin with strict adherence to an antico-
agulation protocol, the prevalence of SCI is signiﬁcantly
reduced. The risk of SCI appears to be limited to patients
with long-standing persistent AF in whom extensive LA
ablation was performed. Importantly, all lesions were small
(o 5 mm) and always were single.
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